Ankylosing Spondylitis Market - Price, Size, Share & Growth

Ankylosing spondylitis (AS) is a rare type of inflammation that mainly affects spine and can damage large joints of body. It causes inflammation in the spinal joints (vertebrae), thereby causing severe pain and discomfort. Over time, ankylosing spondylitis can cause some bones in the spine to fuse together, as a result of which the spine becomes less flexible. Symptoms of ankylosing spondylitis include pain and stiffness in the hips and lower back.

The global ankylosing spondylitis market is estimated to be valued at US$ 4,864.3 million in 2021 and is expected to exhibit a CAGR of 8.2% during the forecast period (2021-2028).

Figure 1.Global Ankylosing Spondylitis Market Share (%) in Terms of Value, by Drug Type, 2021

ANKYLOSING SPONDYLITIS MARKET

To learn more about this report, request sample copy

Increasing prevalence of ankylosing spondylitis is expected to drive the market growth during the forecast period.

The increasing prevalence of ankylosing spondylitis is expected to drive the global ankylosis spondylitis market growth during the forecast period. For instance, according to an article published by ‘Frontiers in Medicine’ journal in March 2021, the epidemiological data in Taiwan stated that the prevalence of ankylosing spondylitis is 96.9 per 100,000 people.

Ankylosing Spondylitis Market Report Coverage

Report Coverage	Details
Base Year:	2020	Market Size in 2021:	US$ 4,864.3 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2021 to 2028
Forecast Period 2021 to 2028 CAGR:	8.2%	2028 Value Projection:	US$ 8,460.7 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug Type: Nonsteroidal anti-inflammatory drugs (NSAIDs), Disease-modifying anti-rheumatic drugs (DMARDs), TNF Inhibitors, Corticosteroids, Others By Route of Administration: Oral, Parentral By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Amgen Inc., AbbVie Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Emcure Pharmaceuticals, Torrent Pharmaceuticals Ltd., UCB S.A., Suzhou Zelgen Biopharmaceuticals Co., Ltd., HENGRUI USA, and Johnson & Johnson Services, Inc.
Growth Drivers:	The rising prevalence of ankylosing spondylitis Increasing launch of biosimilars Increasing research & development efforts being undertaken by key industry players to augment treatment options
Restraints & Challenges:	High cost of treatment Lack of skilled surgeons and physiotherapists

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Figure 2. Global Ankylosing Spondylitis Market Share (%), by Distribution Channel, 2021

ANKYLOSING SPONDYLITIS MARKET

To learn more about this report, request sample copy

Increasing strategic alliances between the companies to develop or to expand the availability of drugs is expected to drive the market growth during the forecast period.

Key players in the market are focusing on inorganic growth strategies, such as partnerships and collaborations which is expected to drive the market growth during the forecast period.

For instance, in August 2021, Inmagene Biopharmaceuticals, a leading biotech company focused on the development of therapeutics for immunology-related diseases, and Affibody AB, a company developing innovative bi- and multi-specific next-generation biopharmaceuticals, working in a partnership, announced the successful dosing of the first patient in the global ASPIRE phase 2 trial evaluating izokibep (IMG-020 or ABY-035) for treating ankylosing spondylitis (AS).

Global Ankylosing Spondylitis Market – Impact of Coronavirus (COVID-19) Pandemic

Accessing medical services can be challenging for people with ankylosing spondylitis during the COVID-19 pandemic. While some drugs for ankylosing spondylitis can be self-administered, some are given through an IV in hospitals. Similarly, physical therapy requires a visit to the physical therapist, which has been difficult due to the COVID-19 pandemic.

Biologics such as TNF (Tumor Necrosis factor) inhibitors, used in ankylosing spondylitis treatment, may increase the risk of infections and lower the body's ability to fight infections, including COVID-19, because these medications cause a suppressing effect on the immune system. Biologics including IL-17 and IL-12/23 inhibitors are used for treating ankylosing spondylitis, but have the same immunosuppressive effect that may increase the risk of infections. Thus, due to this, the growth of the global ankylosing spondylitis market is expected to be hampered.

Ankylosing spondylitis is an immune-mediated inflammatory disease (IMID). According to a study conducted in Ontario, Canada, in 2020, it was found that people with IMIDs were tested for COVID-19 at a 20% higher rate, as compared to the general population.

Global Ankylosing Spondylitis Market: Restraint

The major factors that are expected to hinder growth of the global ankylosing spondylitis market include high cost of treatment and lack of skilled surgeons and physiotherapists.

Key Players

Major players operating in the global ankylosing spondylitis market include Amgen Inc., AbbVie Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Emcure Pharmaceuticals, Torrent Pharmaceuticals Ltd., UCB S.A., Suzhou Zelgen Biopharmaceuticals Co., Ltd., HENGRUI USA, and Johnson & Johnson Services, Inc.

Missing comfort of reading report in your local language? Find your preferred language :

Transform your Strategy with Exclusive Trending Reports :

Hdac Inhibitors Market

Depression Therapeutics Market

Pediatric Nutrition Market

Multiple Sclerosis Therapeutics Market

Hpapis And Cytotoxic Drugs Manufacturing...

Saudi Arabia Pharmaceutical Drugs Marke...

Frequently Asked Questions

The global Ankylosing Spondylitis Market size was estimated at USD 4,864.3 Million in 2024 and is expected to reach USD 4,860.7 Million in 2031.

The global ankylosing spondylitis market size is estimated to be valued at US$ 4,864.3 million in 2021 and is expected to exhibit a CAGR of 8.2% between 2021 and 2028.

Factors such as rising prevalence of ankylosing spondylitis, increasing launch of biosimilars, and increasing research & development efforts being undertaken by key industry players to augment treatment options are expected to drive growth of the market during the forecast period.

Nonsteroidal anti-inflammatory drugs (NSAIDs) drug type segment is expected to hold a major market share during the forecast period.

The major factors hampering growth of the market include high cost of treatment and lack of skilled surgeons and physiotherapists.

Major players operating in the market include Amgen Inc., AbbVie Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Emcure Pharmaceuticals, Torrent Pharmaceuticals Ltd., UCB S.A., Suzhou Zelgen Biopharmaceuticals Co., Ltd., HENGRUI USA, and Johnson & Johnson Services, Inc.